Literature DB >> 10960837

Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate.

U Elsässer-Beile1, B Przytulski, D Gierschner, T Grussenmeyer, A Katzenwadel, C Leiber, A Deckart, U Wetterauer.   

Abstract

BACKGROUND: The presence of lymphocytic infiltration in prostate carcinomas has been shown to have prognostic relevance. However, it is not yet clear if this infiltrate represents a tumor-specific activated cell population or not. Therefore, the aim of the present study was to characterize the activation status of freshly isolated tumor infiltrating lymphocytes (TIL) from prostate carcinomas (PCa) and benign hyperplasia (BPH) with respect to the mRNA expression of cytokines and apoptotic factors.
METHODS: TIL were isolated from mechanically disaggregated tumor material by gradient centrifugation. The cells of the interphase were depleted from epithelial cells with anti-human epithelial antigen magnetic beads and then CD3(+)- lymphocytes were selected with magnetic beads against this determinant. In these pure lymphocyte preparations the mRNA expression of IL-1, IL-10, IFN-gamma, TNF-alpha, Fas and Fas ligand was determined by using a semiquantitative RT-PCR. Contamination with tumor cells was excluded by a PCR for PSA and PSMA.
RESULTS: The CD3(+)-TIL from 21 patients with PCa and 20 patients with BPH expressed significantly higher levels of IL-10- and Fas ligand-mRNA compared to the autologous CD3(+)- PBL, whereas the expression of IL-1-, TNF-alpha- and Fas-mRNA was not different in either cell population. In contrast, the mRNA levels of IFN-gamma were significantly higher only in the CD3(+)-TIL from the carcinomas but not from the BPH compared to autologous CD3(+)-PBL.
CONCLUSIONS: Since high levels of IFN-gamma have been reported to be produced by specifically lytic lymphocytes, our results suggest the presence of specifically activated TIL in the prostate carcinomas but not in the BPH, whereas inflammatory activated TIL are present both in the carcinomas and the BPH. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960837     DOI: 10.1002/1097-0045(20000915)45:1<1::aid-pros1>3.0.co;2-v

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

1.  Characterization of prostate cell types by CD cell surface molecules.

Authors:  Alvin Y Liu; Lawrence D True
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays.

Authors:  Kulkarni Prakash; Gregorio Pirozzi; Michael Elashoff; William Munger; Iwao Waga; Rajiv Dhir; Yoshiyuki Kakehi; Robert H Getzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate.

Authors:  Jessica M Haverkamp; Bridget Charbonneau; Scott A Crist; David K Meyerholz; Michael B Cohen; Paul W Snyder; Robert U Svensson; Michael D Henry; Hsing-Hui Wang; Timothy L Ratliff
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

Review 4.  Chemokines and BPH/LUTS.

Authors:  Jill A Macoska
Journal:  Differentiation       Date:  2011-05-19       Impact factor: 3.880

5.  Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice.

Authors:  Claudia Raja Gabaglia; Alexandra DeLaney; Jennifer Gee; Ramesh Halder; Frank L Graham; Jack Gauldie; Eli E Sercarz; Todd A Braciak
Journal:  J Transl Med       Date:  2010-10-14       Impact factor: 5.531

6.  PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.

Authors:  Wanhua Yang; Peter W Chen; Haochuan Li; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02-22       Impact factor: 4.799

Review 7.  Prostate-associated gene 4 (PAGE4), an intrinsically disordered cancer/testis antigen, is a novel therapeutic target for prostate cancer.

Authors:  Prakash Kulkarni; A Keith Dunker; Keith Weninger; John Orban
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285

8.  Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.

Authors:  Jo A Tucker; Caroline Jochems; James L Gulley; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancers (Basel)       Date:  2012-12-11       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.